Inactive Instrument

News Graf Acquisition Corp. IV Nyse

Equities

GFOR.U

US3842722098

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Graf Acquisition IV : Unaudited Condensed Consolidated Financial Statements - Form 8-K	23-10-05	PU
NKGen Biotech, Inc. Announces Closing of Business Combination	23-10-02	AQ
NKGen Biotech, Inc. completed the acquisition of Graf Acquisition Corp. IV from Graf Acquisition Partners IV LLC, Adage Capital Management, L.P. and others in a reverse merger transaction.	23-09-28	CI
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023	23-09-25	AQ
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023	23-09-22	PR
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023	23-09-14	PR
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023	23-09-11	PR
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023	23-08-30	AQ
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors	23-08-24	AQ
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination	23-08-15	AQ
Graf Acquisition Corp. IV Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company	23-08-09	AQ
Graf Acquisition IV : NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference - Form 8-K	23-07-17	PU
NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event	23-07-06	AQ
GRAF ACQUISITION CORP. IV : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-06-01	AQ
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension	23-05-16	BU
Graf Acquisition Corp. IV Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Graf Acquisition IV : NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV - Form 8-K	23-04-17	PU
GRAF ACQUISITION CORP. IV : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-04-17	AQ
Graf Acquisition Corp. IV Announces Resignation of Sterling Cross as Chief Financial Officer	23-04-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Graf Acquisition Corp. IV Nyse

Equities

GFOR.U

US3842722098

Summary

Filters